LIVZON PHARMA 2025 ESG Report: 19.84% CO₂ Cut, 2055 Net-Zero Goal and RMB1.06 Billion R&D Outlay

Bulletin Express
03/24

LIVZON PHARMA (01513) released its 2025 Environmental, Social and Governance (ESG) Report, presenting material progress on decarbonisation, innovation spend and talent development.

• Carbon trajectory – Total Scope 1+2 emissions fell 8.00 % year-on-year to 488,612 tonnes of CO₂e, 19.84 % lower than the 2020 baseline. – Emission intensity dropped 23.11 % from 2020; the group reaffirmed its 2055 carbon-neutrality target and set 2026-2030 goals to keep Scope 1+2 emissions per RMB10,000 of output at or below 2025 levels. – Scope 3 emissions were quantified for a second year at 589,700 tonnes of CO₂e, with purchased goods and services contributing 35.39 %.

• Resource efficiency – Water use declined 3.84 % from 2020 to 6.03 million tonnes; intensity improved 8.44 % versus 2020. – Total energy consumption edged down to 150,214 tonnes of standard coal equivalent; renewable energy use reached 78,379 MWh. – Environmental capex and O&M spending totalled RMB72.09 million.

• Innovation pipeline and spending – R&D expenditure rose to RMB1.06 billion, 8.79 % of revenue. – The group lists 17 products in Phase III/registration, including two first-in-class assets; 71 S&P Global CSA score places it in the top 5 % of Chinese peers.

• Supply-chain oversight – ESG audits covered 552 direct suppliers and 5 key indirect suppliers; 100 % of suppliers have signed integrity and ESG commitments.

• Workforce and safety – Employees totalled 8,878; females account for 47.60 % of staff and 38.31 % of management. – Zero work-related fatalities; LTIFR for employees at 0.39 per million hours worked. – Occupational health & safety certification reached 100 % of production sites.

• Social investment – Public-interest donations amounted to RMB30.96 million, with the long-running “Accessible and Affordable Chronic Disease Management” programme reaching 48,000 beneficiaries across 37 regions.

LIVZON PHARMA plans to cut water intensity by 5 % and air-pollutant emissions by 10 % versus 2025 levels by 2030 while maintaining current carbon-intensity gains, aiming to align its operations with the 1.5 °C pathway en route to net-zero emissions by 2055.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10